002007.SZ
Hualan Biological Engineering Inc. [002007.SZ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
002007.SZ Stock Summary
Top 10 Correlated ETFs
002007.SZ
Top 10 Correlated Stocks
002007.SZ
In the News
002007.SZ Financial details
Company Rating
Buy
Market Cap
39.66B
Income
1.02B
Revenue
3.75B
Book val./share
5.9
Cash/share
1.95
Dividend
0.3
Dividend %
1.35%
Employees
3.24K
Optionable
No
Shortable
Yes
Earnings
24 Aug 2023
P/E
33.91
Forward P/E
-
PEG
-15.27
P/S
8.51
P/B
3.77
P/C
11.38
P/FCF
53.24
Quick Ratio
2.74
Current Ratio
3.72
Debt / Equity
0.1
LT Debt / Equity
0.03
-
-
EPS (TTM)
0.55
EPS next Y
-
EPS next Q
-
EPS this Y
-16.9%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-1.3%
Revenue last 5Y
7.02%
Revenue Q/Q
-19.99%
EPS Q/Q
-49.53%
-
-
-
-
SMA20
4.76%
SMA50
-
SMA100
-4.35%
Inst Own
-
Inst Trans
-
ROA
8%
ROE
12%
ROC
0.12%
Gross Margin
66%
Oper. Margin
34%
Profit Margin
25%
Payout
33%
Shs Outstand
1.82B
Shs Float
960.64M
-
-
-
-
Target Price
-
52W Range
17.01-25.09
52W High
-11.2%
52W Low
+30.59%
RSI
62
Rel Volume
0.89
Avg Volume
6.8M
Volume
6.05M
Perf Week
0.45%
Perf Month
-0.63%
Perf Quarter
-5.25%
Perf Half Y
0.23%
-
-
-
-
Beta
0.306364
-
-
Volatility
0.2%, 0.41%
Prev Close
-0.05%
Price
22.2
Change
0.27%
002007.SZ Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 1.77 | 2.04 | 2.76 | 2.44 | 2.47 | |
| Net income per share | 0.63 | 0.71 | 0.89 | 0.71 | 0.59 | |
| Operating cash flow per share | 0.71 | 0.75 | 0.73 | 0.79 | 0.52 | |
| Free cash flow per share | 0.61 | 0.6 | 0.39 | 0.34 | 0.31 | |
| Cash per share | 0.23 | 1.86 | 2.21 | 1.84 | 1.9 | |
| Book value per share | 3.05 | 3.6 | 4.14 | 4.58 | 5.7 | |
| Tangible book value per share | 3.06 | 3.67 | 4.34 | 4.85 | 6.51 | |
| Share holders equity per share | 3.05 | 3.6 | 4.14 | 4.58 | 5.7 | |
| Interest debt per share | 0 | 0 | 0.22 | 0.56 | 0.62 | |
| Market cap | 44.57B | 49.12B | 76.79B | 53.06B | 41.3B | |
| Enterprise value | 44.15B | 48.06B | 76.15B | 53.37B | 41.31B | |
| P/E ratio | 39.12 | 38.27 | 47.61 | 40.85 | 38.38 | |
| Price to sales ratio | 13.86 | 13.28 | 15.29 | 11.96 | 9.14 | |
| POCF ratio | 34.48 | 36.05 | 57.94 | 37.04 | 43.14 | |
| PFCF ratio | 40.18 | 45.07 | 109.1 | 85.43 | 73.31 | |
| P/B Ratio | 8.06 | 7.51 | 10.2 | 6.36 | 3.97 | |
| PTB ratio | 8.06 | 7.51 | 10.2 | 6.36 | 3.97 | |
| EV to sales | 13.72 | 12.99 | 15.16 | 12.03 | 9.15 | |
| Enterprise value over EBITDA | 28.38 | 26.56 | 31.7 | 26.27 | 21.78 | |
| EV to operating cash flow | 34.15 | 35.27 | 57.46 | 37.26 | 43.16 | |
| EV to free cash flow | 39.79 | 44.1 | 108.2 | 85.92 | 73.33 | |
| Earnings yield | 0.03 | 0.03 | 0.02 | 0.02 | 0.03 | |
| Free cash flow yield | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Debt to equity | 0 | 0 | 0.05 | 0.12 | 0.11 | |
| Debt to assets | 0 | 0 | 0.04 | 0.09 | 0.08 | |
| Net debt to EBITDA | -0.28 | -0.59 | -0.27 | 0.15 | 0.01 | |
| Current ratio | 6.64 | 8.19 | 3.92 | 3.09 | 3.76 | |
| Interest coverage | 246.15 | 228.22 | 432.74 | 78.09 | 47.06 | |
| Income quality | 1.07 | 0.99 | 0.72 | 0.99 | 0.77 | |
| Dividend Yield | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | 0.24 | 0.3 | 0.35 | 0.43 | 0.37 | |
| Sales general and administrative to revenue | 0.01 | 0.02 | 0.01 | 0.01 | 0.01 | |
| Research and developement to revenue | 0.05 | 0.04 | 0.04 | 0.06 | 0.07 | |
| Intangibles to total assets | 0.03 | 0.03 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -0.14 | -0.2 | -0.47 | -0.57 | -0.41 | |
| Capex to revenue | -0.06 | -0.07 | -0.12 | -0.18 | -0.09 | |
| Capex to depreciation | -1.32 | -1.7 | -3.42 | -4.13 | -1.44 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.56 | 7.57 | 9.09 | 8.57 | 8.69 | |
| ROIC | 0.22 | 0.21 | 0.23 | 0.16 | 0.11 | |
| Return on tangible assets | 0.18 | 0.17 | 0.16 | 0.11 | 0.07 | |
| Graham Net | 0.63 | 2.26 | 2.42 | 1.74 | 1.97 | |
| Working capital | 4.06B | 4.99B | 5.6B | 4.64B | 5.93B | |
| Tangible asset value | 5.55B | 6.67B | 7.88B | 8.84B | 11.88B | |
| Net current asset value | 4.06B | 4.99B | 5.57B | 4.38B | 5.55B | |
| Invested capital | 0 | 0 | 0.05 | 0.12 | 0.11 | |
| Average receivables | 1.04B | 1.13B | 1.73B | 2.22B | 2.36B | |
| Average payables | 66.82M | 65.05M | 113.56M | 201.77M | 208.26M | |
| Average inventory | 1.21B | 1.18B | 1.17B | 1.27B | 1.4B | |
| Days sales outstanding | 126.67 | 113.51 | 167.87 | 175.88 | 208.15 | |
| Days payables outstanding | 21.22 | 18.19 | 43.26 | 63.43 | 41.79 | |
| Days of inventory on hand | 389.94 | 326.4 | 312.67 | 357.6 | 344.48 | |
| Receivables turnover | 2.88 | 3.22 | 2.17 | 2.08 | 1.75 | |
| Payables turnover | 17.2 | 20.07 | 8.44 | 5.75 | 8.73 | |
| Inventory turnover | 0.94 | 1.12 | 1.17 | 1.02 | 1.06 | |
| ROE | 0.21 | 0.2 | 0.21 | 0.16 | 0.1 | |
| Capex per share | -0.1 | -0.15 | -0.34 | -0.45 | -0.22 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0.35 | 0.94 | 0.69 | 0.5 | 0.48 | |
| Net income per share | 0.13 | 0.19 | 0.17 | 0.1 | 0.19 | |
| Operating cash flow per share | 0.03 | 0.19 | 0.17 | 0.1 | 0.19 | |
| Free cash flow per share | -0.05 | 0.19 | 0.15 | -0.01 | 0.09 | |
| Cash per share | 2.67 | 2.68 | 1.98 | 1.9 | 1.95 | |
| Book value per share | 5.44 | 5.44 | 5.61 | 5.7 | 5.9 | |
| Tangible book value per share | 6.23 | 6.2 | 6.42 | 6.52 | 6.72 | |
| Share holders equity per share | 5.44 | 5.44 | 5.61 | 5.7 | 5.9 | |
| Interest debt per share | 0.55 | 0.72 | 0.44 | 0.61 | 0.61 | |
| Market cap | 36.99B | 41.53B | 33.08B | 41.25B | 39.82B | |
| Enterprise value | 35.91B | 40.84B | 32.73B | 41.26B | 40.2B | |
| P/E ratio | 39.54 | 29.74 | 26.04 | 58.7 | 28.31 | |
| Price to sales ratio | 57.74 | 24.3 | 26.4 | 45.1 | 45.21 | |
| POCF ratio | 632.74 | 118.95 | 104.14 | 234.81 | 113.23 | |
| PFCF ratio | -435.28 | 121.42 | 121.96 | -1.93K | 235.77 | |
| P/B Ratio | 3.73 | 4.19 | 3.24 | 3.97 | 3.7 | |
| PTB ratio | 3.73 | 4.19 | 3.24 | 3.97 | 3.7 | |
| EV to sales | 56.06 | 23.9 | 26.12 | 45.11 | 45.65 | |
| Enterprise value over EBITDA | 132.05 | 76.52 | 73.09 | 111.42 | 105.34 | |
| EV to operating cash flow | 614.29 | 116.98 | 103.05 | 234.88 | 114.32 | |
| EV to free cash flow | -422.59 | 119.41 | 120.69 | -1.94K | 238.04 | |
| Earnings yield | 0.01 | 0.01 | 0.01 | 0 | 0.01 | |
| Free cash flow yield | 0 | 0.01 | 0.01 | 0 | 0 | |
| Debt to equity | 0.1 | 0.13 | 0.08 | 0.11 | 0.1 | |
| Debt to assets | 0.07 | 0.09 | 0.05 | 0.08 | 0.07 | |
| Net debt to EBITDA | -3.97 | -1.29 | -0.77 | 0.03 | 1.01 | |
| Current ratio | 3.99 | 3.38 | 3.55 | 3.76 | 3.72 | |
| Interest coverage | 34.64 | 66.07 | 51.95 | 31.19 | 120.94 | |
| Income quality | 0.25 | 1 | 1 | 1 | 1 | |
| Dividend Yield | 0 | 0.01 | 0 | 0 | 0 | |
| Payout ratio | 0.04 | 1.06 | 0.05 | 0.03 | 0.01 | |
| Sales general and administrative to revenue | 0.08 | -0.02 | 0.15 | -0.18 | 0.07 | |
| Research and developement to revenue | 0.1 | 0.05 | 0.06 | 0.1 | 0.09 | |
| Intangibles to total assets | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Capex to operating cash flow | -2.45 | -0.02 | -0.15 | -1.12 | -0.52 | |
| Capex to revenue | -0.22 | 0 | -0.04 | -0.22 | -0.21 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 3.97 | 4.84 | 4.69 | 3.52 | 5.06 | |
| ROIC | 0.02 | 0.04 | 0.04 | 0.02 | 0.03 | |
| Return on tangible assets | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 | |
| Graham Net | 2.64 | 2.62 | 2.25 | 1.97 | 1.94 | |
| Working capital | 6.42B | 6.51B | 5.9B | 5.93B | 5.69B | |
| Tangible asset value | 11.35B | 11.3B | 11.68B | 11.88B | 12.27B | |
| Net current asset value | 6.15B | 6.26B | 5.64B | 5.55B | 5.31B | |
| Invested capital | 0.1 | 0.13 | 0.08 | 0.11 | 0.1 | |
| Average receivables | 2.09B | 2.41B | 2.9B | 2.8B | 2.38B | |
| Average payables | 288.81M | 284.62M | 315.6M | 287.02M | 194.09M | |
| Average inventory | 1.51B | 1.63B | 1.58B | 1.51B | 1.54B | |
| Days sales outstanding | 286.8 | 145.94 | 217.09 | 253.47 | 223.31 | |
| Days payables outstanding | 119.85 | 41.51 | 83.5 | 45.63 | 58.84 | |
| Days of inventory on hand | 594.46 | 282.07 | 329.99 | 376.2 | 453.6 | |
| Receivables turnover | 0.31 | 0.62 | 0.41 | 0.36 | 0.4 | |
| Payables turnover | 0.75 | 2.17 | 1.08 | 1.97 | 1.53 | |
| Inventory turnover | 0.15 | 0.32 | 0.27 | 0.24 | 0.2 | |
| ROE | 0.02 | 0.04 | 0.03 | 0.02 | 0.03 | |
| Capex per share | -0.08 | 0 | -0.03 | -0.11 | -0.1 |
002007.SZ Frequently Asked Questions
What is Hualan Biological Engineering Inc. stock symbol ?
Hualan Biological Engineering Inc. is a CN stock and trading under the symbol 002007.SZ
What is Hualan Biological Engineering Inc. stock quote today ?
Hualan Biological Engineering Inc. stock price is $22.2 today.
Is Hualan Biological Engineering Inc. stock public?
Yes, Hualan Biological Engineering Inc. is a publicly traded company.
Company Profile
- Volume Average 6.8M
- Market Capitalization 39.66B
- Employee 3.24K
- CEO Ms. Bei Fan
- Headquarters Xinxiang,CN
- IPO Date 2004-06-25
-
Website
https://www.hualanbio.com 
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People's Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company's vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine. The company has strategic alliance with the Chinese Academy of Sciences, and other scientific research institutes and scientific research companies. The company was founded in 1992 and is based in Xinxiang, the People's Republic of China.
